Vicarious Surgical Inc. has outlined a strategic plan aimed at strengthening its financial position and pursuing a potential relisting on the Nasdaq Capital Market, as the robotics technology company continues to advance its minimally invasive surgical platform.
The company, currently trading on the OTCID market tier under the ticker RBOT, is undertaking a series of operational and capital markets initiatives designed to improve cost efficiency, enhance trading liquidity, and position itself for a return to a national exchange.
Over recent months, Vicarious Surgical has implemented cost discipline measures to better align its operating structure with its current stage of development. These changes include increased use of outsourcing and broader operational efficiencies, enabling the company to significantly reduce its projected cash burn. For full-year 2026, the company expects cash burn to decline to approximately $19 million, compared with prior guidance of around $35 million in late 2025 and roughly $50 million at its mid-2025 operating level.
Despite these cost reductions, the company indicates that progress on its core technology roadmap remains intact. Development of the Vicarious Surgical System is ongoing, with the company targeting system design freeze by the end of 2026—a key milestone in its regulatory and commercialization pathway.
Based on its current operating plan, Vicarious Surgical expects its existing cash reserves to support operations through the second quarter of 2026. This financial runway is expected to provide the company with sufficient time to execute its broader capital markets strategy.
As part of this strategy, the company has submitted an application to list its Class A common stock on the Nasdaq Capital Market. In parallel, it has filed a preliminary proxy statement with the U.S. Securities and Exchange Commission seeking shareholder approval for a potential reverse stock split. The move is intended to help the company meet Nasdaq’s minimum bid price requirement for listing.
Vicarious Surgical is also evaluating potential capital-raising options to support continued development of its robotic surgical system and to meet applicable listing criteria. However, the company noted that there can be no assurance that it will satisfy Nasdaq’s listing standards or complete any proposed financing initiatives.
In the interim, the company is working to improve trading visibility and liquidity in the over-the-counter market. Following its transition from the New York Stock Exchange, Vicarious Surgical has applied to upgrade its listing to the OTCQB Venture Market, a tier designed for early-stage and growth-oriented companies. The company believes that an OTCQB quotation could enhance market participation and improve liquidity as it works toward a potential relisting.
Commenting on the developments, Stephen From, Chief Executive Officer of Vicarious Surgical, said the company has taken “decisive steps” to streamline operations and reduce cash burn while maintaining progress on key development timelines. He added that the company is actively pursuing a return to a national exchange and believes the current initiatives strengthen its long-term foundation.
